NA Selank Amidate

Selank, also known as TP-7 or Thr-Lys-Pro-Arg-Pro-Gly-Pro, is a synthetic neurotrophic peptide developed for research applications. This anxiolytic peptide is designed to mimic the effects of tuftsin, a naturally occurring tetrapeptide involved in immune modulation. The compound operates through a sophisticated mechanism involving neurotransmitter balance regulation, particularly affecting serotonin and dopamine pathways that are crucial for mood regulation in research models. Studies indicate that Selank enhances the expression of brain-derived neurotrophic factor (BDNF), which supports neuronal growth and synaptic plasticity in laboratory investigations. Research has demonstrated several primary effects in experimental models, including anxiety reduction without sedation, cognitive function and memory improvements, enhanced mood and emotional stability, immune response modulation, and increased resilience to stress. The evidence grade is classified as B, with several human trials conducted in Russia suggesting effectiveness in reducing anxiety and improving cognitive function in research settings. However, current research limitations include a restricted number of studies and often inadequate rigorous controls. More extensive, placebo-controlled trials are needed to confirm these preliminary findings. The regulatory landscape is evolving, with FDA Category 2 reclassification to Category 1 expected following announcements in February 2026. This research-grade peptide offers valuable opportunities for investigating neurotrophic mechanisms, neurotransmitter modulation, and cognitive enhancement pathways in controlled laboratory environments.